EGFR and non-small cell lung carcinoma: This study introduces a RL-based approach to guide TKI treatment selection for advanced EGFR-mutant NSCLC, incorporating patient, disease, and treatment features, along with the neutrophil-to-lymphocyte ratio (NLR)—a biomarker reflecting the balance between inflammatory and immune responses.